Effect of erythropoietin on primed leucocyte expression profile

Mirko Pesce1, Paolo Felaco2, Sara Franceschelli2, Lorenza Speranza2, Alfredo Grilli2, Maria Anna De Lutiis2, Alessio Ferrone2, Vittorio Sirolli2, Mario Bonomini2, Mario Felaco2 and Antonia Patruno2

1Department of Psychological, Humanistic and Territorial Sciences, and 2Department of Medicine and Science of Aging, University ‘G. D’Annunzio’, Chieti, Italy

1. Summary

Resistance to erythropoietin (EPO) affects a significant number of anaemic patients with end-stage renal disease. Previous reports suggest that inflammation is one of the major independent predictors of EPO resistance, and the effects of EPO treatment on inflammatory mediators are not well established. The aim of this study was to investigate EPO-induced modification to gene expression in primary cultured leucocytes. Microarray experiments were performed on primed ex vivo peripheral blood mononuclear cells (PBMCs) and treated with human EPO-α. Data suggested that EPO-α modulated genes involved in cell movement and interaction in primed PBMCs. Of note, EPO-α exerts anti-inflammatory effects inhibiting the expression of pro-inflammatory cytokine IL-8 and its receptor CXCR2; by contrast, EPO-α increases expression of genes relating to promotion of inflammation encoding for IL-1β and CCL8, and induces de novo synthesis of IL-1α, CXCL1 and CXCL5 in primed cells. The reduction in MAPK p38-α activity is involved in modulating both IL-1β and IL-8 expression. Unlike the induction of MAPK, Erk1/2 activity leads to upregulation of IL-1β, but does not affect IL-8 expression and release. Furthermore, EPO-α treatment of primed cells induces the activation of caspase-1 upstream higher secretion of IL-1β, and this process is not dependent on caspase-8 activation. In conclusion, our findings highlight new potential molecules involved in EPO resistance and confirm the anti-inflammatory role for EPO, but also suggest a plausible in vivo scenario in which the positive correlation found between EPO resistance and elevated levels of some pro-inflammatory mediators is due to treatment with EPO itself.

2. Introduction

Anaemia is an inevitable condition that develops early in the course of chronic kidney disease (CKD) and increases in frequency while the glomerular filtration rate further declines [1]. With the advent of erythropoiesis-stimulating agents (ESAs) in the 1990s, great improvements were achieved in the treatment of anaemia in the majority of patients with end-stage renal disease, but 10% of all treated patients remained anaemic despite large ESA doses; those patients are therefore considered resistant to ESA treatment [2,3]. A number of factors have been implicated as contributors to ESA resistance, though persistent inflammation with higher levels of pro-inflammatory cytokines is
increasingly being appreciated as the major cause of EPO hyporesponsiveness [4–7].

Pro-inflammatory cytokines simultaneously affect erythropoiesis at several levels, and manifest their effects as ‘inflammation anaemia’ and hyporesponsiveness to EPO treatment in patients with CKD [8]. Pro-inflammatory cytokines can, indeed, cause EPO resistance, inhibiting the in vitro growth of erythroid progenitors [9–11] and interfering with iron homeostasis. In particular, tumour necrosis factor (TNF-α), IL-1 and IL-6 increase the expression of divalent metal transporter-1, induce ferritin synthesis, reduce ferroportin expression and stimulate the transferrin-bound iron reuptake by increasing the transferrin receptor expression in macrophages. TNF-α and IL-1 can also damage the erythrocyte membranes and stimulate erythrocyte phagocytosis [12,13]. All these processes promote the intracellular accumulation of iron by reducing its bioavailability, reduce the production of endogenous EPO as well as the bone marrow response to the erythropoietic stimulus, and end by making and keeping patients anaemic [14].

EPO is a multi-functional cytokine, which exerts erythropoietic and immune-modulatory effects upon binding to two distinct receptors, which are expressed on erythroid, parenchymal and immune cells [15]. The bond between EPO-α and EPO receptor (EPOR) in peripheral blood mononuclear cells (PBMCs) leads to a reduction in inflammation [16,17]. However, EPO administration was also found to further augment the lipopolysaccharide (LPS)-induced increase in plasma levels of TNF-α and IL-6, and to attenuate the decrease in lymphocyte number [18]. Again, it has been reported that anaemia in CKD is associated with upregulation of TNF-α, along with increased levels of this pro-inflammatory cytokine in patients treated with ESAs [19]. These findings suggest that the effects of EPO treatment on inflammatory mediators are strictly dependent on the phase and intensity of the inflammatory condition present during drug administration.

Hence, inflammation markers may be considered sensitive outcome predictors in patients suffering from CKD and thus involved in EPO resistance. Gene expression being a sensitive endpoint, a microarray can be useful in monitoring the exposure effect and identifying any new biomarkers. Accordingly, in this study, we applied gene expression microarray technology to identify the differentially expressed genes in PBMCs, primed or not, when exposed to human recombinant erythropoietin-α (EPO-α). We chose PBMCs because they are the main source of inflammation mediators, present EPOR on their membrane, and have been defined as surrogate markers and key mediators in low-grade inflammation associated with renal failure. These cells may exist in the bloodstream in a quiescent, primed or activated state. The ‘primed’ state involves PBMCs first encountering a stimulus [20]. Keeping in mind that patients who are hyporesponsive to ESAs show high baseline serum levels of TNF-α correlated with a negative response to ESAs, PBMCs primed cells were obtained by exposure to this pro-inflammatory cytokine [21].

### 3. Material and methods

#### 3.1. Chemicals

The following were used: TNF-α (Enzo Life Science, Lousen, Switzerland); LPS (Escherichia coli 0127:B), MAPK p38 inhibitor SB203580, Erk1/2 inhibitor PD98059, Caspase-1 inhibitor Ac-YVAD-cmk, Caspase-8 inhibitor Z-IETD-FMK (Sigma, St. Louis, MO); recombinant human EPO-α (RayBiotech, Norcross, GA).

#### 3.2. Cell culture

Buffy coats were collected from the blood of 10 healthy individual donors from the Transfusion Blood Bank Services of Chieti, Italy. All donors gave informed consent and no individuals were taking medication. PBMCs were isolated as previously described [22]. The cell viability, determined by trypan blue exclusion, was more than 99%. The same batch of serum and medium was used in all experiments. The media and sera were characterized by very low LPS content as determined by testing the chromogenic assay using limulus amoebocyte lysate (minimum detection level 0.1 μg ml−1; Whittaker Bioproducts, Walkersville, MD). PBMCs obtained from each subject were prepared following the same experimental procedure and divided into four samples for microarray experiment: (i) control cells, (ii) cells stimulated with TNF-α (10 ng ml−1, 30 min), (iii) cells stimulated with EPO-α (20 U ml−1, 15 min), and (iv) cells pre-stimulated with TNF-α (10 ng ml−1, 15 min) and then treated with EPO-α (20 U ml−1, 15 min). EPO-α was used at a concentration of 20 U ml−1, which has previously been shown significantly to attenuate polymorphonuclear leucocyte (PMNL) priming and PMNL-associated systemic low-grade inflammation [23]. The inhibitor of MAPK p38 (SB203580) or Erk1/2 (PD98059) was used at a concentration of 1 μM and added 30 min prior to TNF-α stimulation; antibody anti-EPO (MAB287, R&D Systems, Minneapolis, MN) was used at a concentration of 10 μg ml−1 and added 30 min prior to EPO-α stimulation [24]. LPS was used at a concentration of 10 μg ml−1 [22]; Caspase-1 inhibitor Ac-YVAD-cmk or Caspase-8 inhibitor Z-IETD-FMK was used at a concentration of 10 and 20 μM, respectively, and added 1 h prior EPO-α stimulation [25,26]. Cells were seeded onto six-well tissue culture plates and incubated overnight at 37 °C in a humidified atmosphere of 5% CO₂.

#### 3.3. Microarray

Total RNA extraction from human PBMCs was performed using Trizol reagent (Invitrogen, Carlsbad, CA). The RNA concentration and purity were determined by measuring absorbencies at 260 and 280 nm, a 260 : 280 ratio of 1.9 being considered acceptable for analysis. The extracted RNA was first run on a denaturing gel to make sure that two bright distinct bands, representing the 28S and 18S ribosomal species, were found. This confirmed that the RNA lacked DNA contamination and was not degraded, both of which might confound the array results. Analysis was carried out using a high-density array containing about 30,968 human genome probes and 1082 experimental control probes (60-mer sense-strand polynucleotide probes; Eurogentec, Seraing, Belgium) [27]. Briefly, 100 ng of RNA of each buffy coat (n = 10) were pooled for all four samples and then amplified using the Ammono Allyl MessageAmp II aRNA Amplification Kit (Ambion, Austin, TX), which is able to produce aRNA, containing 5-(3-aminoallyl)-UTP-modified nucleotides. The aRNA (5–20 μg) obtained was labelled with Cy3 or Cy5 fluorochromes (Amersham, Pharmacia Biotech, Buckinghamshire, UK) and hybridized on the array. aRNA
obtained from control cells (1) was labelled with Cys3 (Cys5 in dye swap experiments). aRNA obtained from samples—cells stimulated with TNF-α (2), cells treated with EPO-α (3) and cells treated with EPO-α after stimulation with TNF-α (4)—was labelled with Cys5 (Cys3 in dye swap experiments). Each experiment was performed using different microarray slides, in which labelled aRNA from control cells (1) was hybridized with labelled aRNA from sample 2 or 3 or 4. Fluorescent signals were captured by ScanArray 5000 Packard laser scanning (Packard BioChip Technologies, Billerica, MA) and normalized using SCANARRAY EXPRESS software. Microarray data are deposited in the GEO public database (accession no.: GSE53336). All data are MIAME compliant.

### 3.4. Real time PCR

Total RNA was extracted in the same way as for microarray. RNA (1 μg) from each buffy coat (n = 10) for all four samples was treated with DNase I (Fermentas) and cDNA was obtained using the ‘high-capacity cDNA’ kit (Applied Biosystems), according to the manufacturer’s instructions.

A qPCR assay was carried out in an Eppendorf Mastercycler EP Realplex (Eppendorf AG). Preliminary qPCR reactions were run to optimize the concentration and ratio of each primer set. For all the cDNA templates, 2 μl was used in a 20 μl qPCR amplification system provided by the SYBR Green Real Master Mix Kit, according to the manufacturer’s directions. Primers for human IL1A, IL1B, CCL8, CXCL1, CXCL5, IL8 and CXCR2 and GAPDH as a reference gene (table 1) were designed using GeneWORKS software (IntelliGenetix, Mountain View, CA).

Similar amplification procedures and data computation were followed as described above. No qPCR products were generated from genomic versus cDNA template. Melting curve analysis was performed to confirm the purity of the qPCR products. Relative expression of IL1A, IL1B, CCL8, CXCL1, CXCL5, IL8 and CXCR2 was normalized to GAPDH using the ΔCT method (relative expression = 2−ΔCT, where ΔCT = CT (IL1A; IL1B; CCL8; CXCL1; CXCL5; IL8; CXCR2) − CT(GAPDH)). Quantification cycle (Cq) values were exported directly onto EXCEL worksheets for analysis. Relative changes in gene expression were determined by the 2−ΔΔCT method as described previously [28] and reported as the difference (n-fold) relative to the value for a calibrator cDNA (control) prepared in parallel with the experimental cDNAs. DNA was denatured at 95°C for 2 min followed by 40 cycles of 30 s at 95°C together with 30 s at 60°C. The experiments were repeated twice with consistent results.

### 3.5. ELISA

Quantitative measurement of human cytokines was assayed using specific ELISA development systems to detect IL-1β, IL-1α and IL-8 (Searchlight, Aushon Biosystems, MA) in accordance with the manufacturer’s instructions.

### 3.6. Western blotting

Western blotting was performed as described below [29]. Briefly, total protein extracts were prepared by treating cells with lysis buffer (RIPA). In Western blot analysis, 50 μg of protein per lane was separated on a 4–12% NuPAGE gradient gel (Gibco Invitrogen, Paisley, UK). Blots were probed and incubated with rabbit polyclonal IgG anti-p38, anti-p-p38 (Thr 180/Tyr 182), anti-Erk1/2, anti-p-Erk1/2 (Thr202/Tyr204), anti-CXCL1, anti-CXCL5 and anti-CCL8 (Santa Cruz Biotechnology, Santa Cruz, CA) at 0.2 μg ml−1 in Tris-buffered saline 0.1% Tween-20. A mouse anti-human monoclonal antibody recognizing the human β-actin (A5441; Sigma-Aldrich) was used as control in all experiments. Immunoblot signals were developed using Super

### Table 1. Sequences of human primers used for qPCR analysis.

| species     | gene name | reference sequence | primers                                      |
|-------------|-----------|--------------------|----------------------------------------------|
| Homo sapiens| GAPDH     | NM_002046          | For: GCGCCCAATACGACCAA                        |
|             |           |                    | Rev: GCTCTCTGCTCCTCTCTGTT                    |
|             | IL1A      | NM_000575.3        | For: TCCCAATCTCAATTCCAACAC                   |
|             |           |                    | Rev: CTCTACCAAGGACACAGAGAGAGAA               |
|             | IL1B      | NM_000576.2        | For: CAAGGGGCGGCGGATATAA                     |
|             |           |                    | Rev: CTAAGGATGATGACACATTCA6G                 |
|             | CXCL1     | NM_001511.3        | For: GGAACAGAAGGGAAAGAGAGAGAGAGA             |
|             |           |                    | Rev: TAGGAAGGTGTCGAGTTAGA                     |
|             | CXCL5     | NM_002994.3        | For: CCTGAAAGACGGGAGAGAGGGAA                 |
|             |           |                    | Rev: CTGGTGGAAGCTGGGAAGCT                  |
|             | IL8       | NM_000584.3        | For: CTGGGAGCTCTGGATGTT                     |
|             |           |                    | Rev: GGGTGAAGGTGTTGGAGATG                  |
|             | CXCR2     | NM_001557.3        | For: CTGCTGATGGTGTCATTTAT                    |
|             |           |                    | Rev: CAAGCTGAGGGCGGAAGAGTAG                 |
|             | CCL8      | NM_005623.2        | For: TOACTGTTCCCTCCCTCACCT                  |
|             |           |                    | Rev: GCACGTAGTGGCAGGAAGAATTACC              |
3.7. Statistical analysis

Data were analysed using paired *t*-test statistics with SPSS 18.0.1 (SPSS, Chicago, IL) for Windows. Results are described as mean ± s.d. for each assessment performed at least in triplicate. The level of statistically significant difference was defined as *p* < 0.05. p38α and p-p38α, and Erk1/2 and p-Erk1/2 levels at each time point were compared by non-parametric Mann–Whitney *U*-test with Bonferroni correction.

The microarray-obtained data were statistically analysed using the SAM system (where SAM is significance analysis of microarray). Genes were median centred and SAM multiclass analysis was performed. Missing values were calculated using the K-nearest-neighbour algorithm set to 100. A false discovery rate = 0% was used for multiclass analysis.

**Ingenuity Pathway Analysis** (IPA, v. 8.8) software (Mountain View, CA) was used to identify the association between the uploaded genes with the biological functions and canonical pathways present in the Ingenuity Pathways Knowledge Base. The Benjamini–Hochberg multiple testing correction was applied to determine the level of significance of biological functions (*p* < 0.001). Fisher’s exact test was applied to determine the significance of pathway associations (*p* < 0.01). A Z-score of more than or less than 2 was accepted for prediction analysis.

### Table 2. Functions significantly modulated in the gene list.

| function | B–H *p*-value | molecules |
|----------|---------------|-----------|
| cellular movement | 5.71 × 10⁻⁷ – 6.84 × 10⁻² | CIB1, IL8, IL1B, F1N1, THBS1, EGR1, DGKA, CD36, S100A4, CXCL1, CXCL5, CLIC4, CTSZ, CLEC11A, CD9, CXCR2, PECAM1, CCL8, CD151 |
| hair and skin development and function | 5.71 × 10⁻⁷ – 6.84 × 10⁻² | IL8, IL2, F1N1, CXCR2, THBS1, CD36, CXCL1, CXCL5 |
| cardiovascular system development and function | 2.32 × 10⁻⁶ – 6.84 × 10⁻² | IL8, IL1A, F1N1, THBS1, DGKA, CXCL1, CD36, CXCL5, CLIC4, LPAR6, CD9, CXCR2, PECAM1, CD151 |
| haematological system development and function | 4.22 × 10⁻⁶ – 6.84 × 10⁻² | MRC1, IL8, IL1A, F1N1, THBS1, CXCL1, CCL8, CXCL5, LILRB1, CTSZ, CLEC11A, CD9, CXCR2, PECAM1, CCL8, CD151, MAOA |
| immune cell trafficking | 4.22 × 10⁻⁶ – 6.84 × 10⁻² | MRC1, IL8, IL1A, F1N1, THBS1, CXCL1, CCL8, CXCL5, LILRB1, CTSZ, CXCR2, PECAM1, CCL8, CD151 |
| cell-to-cell signalling and interaction | 1 × 10⁻⁴ – 6.84 × 10⁻² | MRC1, IL8, IL1A, F1N1, THBS1, CXCL1, CD36, CXCL5, LILRB1, CTSZ, CLEC11A, CD9, CXCR2, PECAM1, MAP1L1, CD151 |
| tissue development | 1 × 10⁻⁴ – 6.08 × 10⁻² | CIB1, MRC1, IL8, IL1A, F1N1, THBS1, EGR1, CD36, DXD9, CXCR2, PIP4M1, PECAM1, MAP1L1, CD151 |
| cell morphology | 3.16 × 10⁻⁴ – 6.84 × 10⁻² | CIB1, IL8, TNFRSF9, IL1A, F1N1, THBS1, CXCL1, CLIC4, AMD1, CTSZ, PCL170, LPAR6, SCN1B, CD9, CXCR2, PIP4M1, PECAM1, MAP1L1, CCL8, CANSB, CD151 |
| connective tissue development and function | 2.24 × 10⁻⁴ – 6.84 × 10⁻² | IL8, IL1A, F1N1, THBS1, CXCR2, CD36, TNFAIP3 |
| skeletal and muscular system development and function | 5.35 × 10⁻⁴ – 6.44 × 10⁻² | IL8, IL2, IL1A, F1N1, THBS1, S100A4, TNFAIP3, CLIC4 |

### 4. Results

#### 4.1. Microarray analysis

SAM multiclass analysis was performed among the gene expression variations obtained from three classes: control cells versus cells primed with TNF-α, control cells versus cells treated with EPO-α, control cells versus cells treated with both stimuli. The analysis generated a significantly perturbed list of 124 genes (FDR = 0%) that was uploaded onto IPA (Ingenuity Systems, Redwood City, CA) for assignment of biological functions as well as to identify any perturbed signal transduction pathways. Electronic supplementary material, file S1 shows the complete gene list analysed. The results showed that the biological functions modulated by treatment with each stimulus alone or in combination involved key functions of immune system regulation. The most significant are listed in table 2 (B–H, *p* < 0.001). The alteration of gene expression is mainly implicated in regulation of cellular development, though also in PBMC dynamic processes, such as cell movement and cell-to-cell interaction.

The pathway analysis was performed upon cytokine signalling. The analysis revealed significant differential expression for genes involved in IL-1 signalling (*p* < 0.01). Thus, IPA predicted significant activation for IL-1α in inducing upregulation of itself and other pro-inflammatory mediators in PBMCs treated with both stimuli (Z-score of more than 2). These genes encode for chemokines CXCL1, CXCL5 and CCL8. Table 3 shows the values of fold change (FC) for the above-mentioned genes and for the β isoform.
of IL-1. Variations of the expression reported for the β isofrom of IL-1 showed induction upon stimulation with TNF-α, and induction of higher intensity when cells were treated with both stimuli. However, the high variability between replicates obtained did not allow this cytokine to be included in the list of significant genes, and called for further quantitative assessment which will be described below.

The anti-inflammatory action of EPO-α transpires from the normalization of the expression on the transcript of pro-inflammatory cytokine IL-8 and the downregulation of gene coding for its receptor CXCR2. Also, the gene encoding for kinase Feline Sarcoma Oncogene (FES), involved in regulating the hematopoietic process and chemotaxis, is significantly downregulated in cells treated with both stimuli.

### 4.2. Microarray validation data

In order to quantitatively evaluate the changes to gene expressions obtained by microarray, we performed qPCR experiments. Table 4 shows that the expression levels follow trends observed in microarray analyses (n.s., not significant).

| Gene   | TNF-α | EPO-α | TNF-α + EPO-α |
|--------|-------|-------|---------------|
|        | FC (mean ± s.d.) | FC (mean ± s.d.) | FC (mean ± s.d.) |
| IL1A   | n.s.  | n.s.  | 5.68 ± 1.35a  |
| IL1B   | 2.86 ± 2.53 | n.s.  | 7.87 ± 6.08  |
| IL8    | 3.19 ± 1.27a | n.s.  | n.s.          |
| CXCL1  | n.s.  | n.s.  | 3.19 ± 0.40a  |
| CXCL5  | n.s.  | n.s.  | 3.34 ± 0.55a  |
| CCL8   | 2.26 ± 1.19a | n.s.  | 6.12 ± 1.65a  |
| CXCR2  | n.s.  | n.s.  | −4.54 ± 1.72a |
| FES    | n.s.  | n.s.  | −1.71 ± 0.16a |

\(^a\)Significant genes considering the FDR = 0%.

Next, we investigated by Western blotting experiments whether the modulation exerted by EPO-α on primed cells was also induced at protein level. As shown in figure 1, the CXCL1, CXCL5 and CCL8 protein levels present similar trends observed in microarray and qPCR analyses. We also observed the same trend in measuring the release of IL-1α in conditioned medium of PBMCs under the same experimental conditions (figure 1d). These data suggest that there did not occur any post-transcriptional regulation mechanisms during these processes.

### 4.3. Role of MAPK p38α and Erk1/2 activations on erythropoietin-α regulation of IL-8 and IL-1β expression and release in primed peripheral blood mononuclear cells

Since our data suggested some controversial effects by EPO-α on pro-inflammatory mediators, particularly on TNF-α upregulation of IL-1β and IL-8, we further investigated the mechanisms involved in this process, analysing the expression of MAPK p38α and Erk1/2, and their relative phosphorylated isoforms. The role of p38 has been previously described with regard to IL-8 expression regulation in several cell types stimulated with TNF-α [30–32]. Several reports showed that p38 could be involved in resolution of inflammation and thus in negative regulation of pro-inflammatory cytokine expression [33–36]. Furthermore, the involvement of Erk1/2 has been associated with IL-1β induction [37,38].

As shown in figure 2a, the treatment of PBMCs with TNF-α induced a higher level of p-p38α Thr180/Tyr182 protein than quiescent cells (0 min), and the peak of induction was observed at 30 min after TNF-α stimulation (p < 0.01). Figure 2b shows the effects of the EPO-α treatment on p-p38α protein expression. The treatment with EPO-α alone does not affect p-p38α levels when applied to control cells, whereas the treatment with EPO-α significantly decreases the level of phosphorylated form of p38α (p < 0.05). Blockage of EPO-α with a specific Ab anti-EPO significantly abrogates the EPO-α reduction of p-p38α in primed PBMCs.

In addition, the treatment of PBMCs with TNF-α induced a higher level of p-Erk1/2 Thr202/Tyr204 protein, with the peak of induction observed at the same time as p-p38α (figure 2c). Unlike from p38, the EPO-α treatment significantly increases on the levels of p-Erk1/2 expression in primed cells (p < 0.05) when compared with TNF-α stimulated cells (figure 2d). As shown for p-p38 expression modulation, pre-treatment of PBMCs with specific Ab anti-EPO abrogates the effect on p-Erk1/2 expression.

In order to better clarify the role of EPO-α in pro-inflammatory cytokine IL-1β and IL-8 gene expression, SB203580 and PD98059 were used to treat PBMCs as a MAPK p38α and Erk1/2 selective inhibitor, respectively. qPCR experiments were performed. The results shown in table 5 suggest that inhibition of p38 activity significantly reinforces the trends observed for IL-1β and IL-8 expression in primed cells treated with EPO-α. In detail, we observed that p38 inhibition further increased IL-1β expression in primed PBMCs treated with EPO-α. Again, pre-treatment with SB203580 inhibitor significantly abrogated the expression normalization of IL-8 exerted by treating primed cells with EPO-α.

The pre-treatment of primed cells stimulated with EPO-α with PD98059 significantly reduced the mRNA amount of IL-1β, but did not affect those of IL-8. Thus, as far as MAPK Erk1/2 is concerned, our findings suggest the involvement of this kinase in mediating the EPO-α induction of IL-1β expression. Again, these expression modulations were completely blocked by Ab anti-EPO-α, suggesting that bound EPO/EPOR occurs in this process.

Of note, we did not observe significant modulation in treating cells with MAPK inhibitors alone (table 5).

The cytokine biological effects were elicited by protein product. In particular, IL-1β is expressed at the transcriptional level as a precursor form, while only the active form is cleaved and secreted. Subsequently, we performed ELISA measurements for these cytokines, comparing how they were released in the conditioned medium of primed PBMCs when compared with EPO-α.

The release of IL-8 in conditioned medium of PBMCs showed a similar trend to that reported for the expression level (figure 3b). Furthermore, we observed increased secretion of IL-1β after stimulation with TNF-α and a still higher...
From at least three independent experiments, each performed in triplicate (Western blot analysis of immunoreactive band was analysed by densitometry and normalized to β-actin levels). ELISA measurement of IL-1α levels in conditioned medium of PBMCs.

The medium levels of IL-1α increase in primed cells treated with EPO-α (*p < 0.05). Results are expressed in picogram per millilitre (mean ± s.d.). In all experiments, data shown are expressed as mean ± s.d.; *p < 0.05 compared with PBMCs primed with TNF-α; **p < 0.05 compared with control PBMCs; data were from at least three independent experiments, each performed in triplicate (n = 9).

**Figure 1.** Effect of EPO-α on protein expressions of chemokines and release of IL-1α. PBMC cells were treated with TNF-α and/or EPO-α at the doses indicated. Western blot analysis of (a) CXCL-1, (b) CXCL-5 and (c) CCL8 expression in PBMCs. Cells were pre-treated or not with TNF-α and then treated with EPO-α. Each immunoreactive band was analysed by densitometry and normalized to β-actin levels. (d) ELISA measurement of IL-1α levels in conditioned medium of PBMCs.

**4.4. Effect of protease inhibitors on IL-1β secretion by primed peripheral blood mononuclear cells treated with erythropoietin-α**

The caspases were proteases strictly classified into two sub-families depending on whether they controlled inflammation, such as caspases-1 (CASP-1), or apoptotic cell death, such as caspases-8 (CASP-8). The CASP-1 activations are dependent on the inflammasomes and their cytosolic activation platform; CASP-1 then catalyse the proteolytic maturation of pro-inflammatory cytokines IL-1β and IL-18 [39]. However, recent findings suggested that the CASP-8 also exert non-apoptotic roles in inflammation and immunity [40].

In order to verify whether EPO-α acts as inflammasome activator in eliciting IL-1β secretion in primed cells, we performed ELISA experiments on conditioned medium of PBMCs. The cells were primed with TNF-α or LPS, pre-treated with CASP-1 or CASP-8 selective inhibitor and then treated or not with EPO-α. The data reported in figure 4 suggest that EPO-α treatment of cells primed with LPS showed a higher amount of released IL-1β versus cells primed with TNF-α. Of note, pre-treatment of primed PBMCs with CASP-1 selective inhibitor significantly abrogates these processes, but we did not report any variations inhibiting CASP-8 activity under the same experimental conditions.

|        | IL1A | IL1B | CXCL1 | CXCL5 | IL8  | CXCR2 | CCL8 |
|--------|------|------|-------|-------|------|-------|------|
| CTRL   | 1.00 ± 0.04 | 1.00 ± 0.08 | 1.00 ± 0.12 | 1.00 ± 0.14 | 1.00 ± 0.32 | 1.00 ± 0.18 | 1.00 ± 0.21 |
| TNF-α  | 1.07 ± 0.17 | 2.53 ± 0.12** | 1.17 ± 0.13 | 1.05 ± 0.25 | 3.45 ± 0.19** | 1.09 ± 0.17 | 2.48 ± 0.15** |
| EPO-α  | 0.94 ± 0.10 | 0.97 ± 0.11 | 1.05 ± 0.18 | 1.04 ± 0.19 | 0.97 ± 0.12 | 0.96 ± 0.16 | 1.14 ± 0.19 |
| TNF-α + EPO-α | 3.05 ± 0.69* | 6.05 ± 0.15* | 2.99 ± 0.26* | 3.33 ± 0.27* | 1.05 ± 0.45* | 0.32 ± 0.19* | 4.72 ± 0.11* |

*p < 0.05 versus cells treated with TNF-α, **p < 0.05 versus control PBMCs.
and (b) was analysed by densitometry and normalized to (c) EPO-α cytos primed and unprimed show different responses to modulation as exerted by EPO-α treatment. We analysed these genes strictly in relation to a role in specific immunity functions such as migration and cell–cell interactions, suggesting that, at least in vitro, leucocytes primed and unprimed show different responses to EPO-α treatment. We analysed these genes strictly in relation to cytokine signalling and observed that the signalling of IL-1 is significantly modulated by TNF-α/EPO-α synergy. Treatment with EPO-α further increased the TNF-α induction of gene expression and secretion of active forms of IL-1β, and stimulated de novo expression of IL-1α in primed cells. In particular, we observed an additive effect by EPO-α on IL-1β, which proves higher for the release of the active form in conditioned medium, when compared with the increase in the precursor form at a transcriptional level. These findings suggest that under our experimental conditions, EPO could act as a secretor stimulus on primed PBMCs. We hypothesized that this process is dependent on the interaction exerted by EPO on CASP-1, a key component of the inflammasome, which leads to IL-1β precursor activation [42], but not CASP-8 activity; this induction was indeed annulled by pre-treatment of cells with CASP-1 selective inhibitor (Ac-YVAD-AMK), but not when PBMCs were pre-incubated with selective CASP-8 inhibitor (Z-IETD-FMK). In accordance with the above fact, microarray analysis suggested that the CASP-8 gene is significantly downregulated in primed cells treated with EPO-α and/or anti-EPO-α (top). Each immunoreactive band was analysed by densitometry and normalized to (b) p38-α or (d) Erk1/2 levels (mean ± s.d., n = 6) (bottom). *p < 0.01 versus TNF-α-α-treated cells, #p < 0.01 versus TNF-α- and EPO-α-treated cells.

5. Discussion

In past years, increasing evidence of associations between chronic inflammation and hyporesponsiveness to erythropoietin stimulation warranted investigation of the molecules characterizing the process, which might prove useful as new therapeutic targets. EPO hyporesponsiveness/resistance seems to be due to several interacting factors, such as an altered ratio of cytokines stimulating and inhibiting erythropoiesis as well as interference with post-receptor intracellular signalling between pro-inflammatory cytokines and ESAs. Furthermore, the effects of ESA treatment on inflammation mediators proved controversial and needed further investigation [41]. Thus, we focused our attention on expression modulation as exerted by EPO-α on primed PBMCs, and started functional analysis of the kinases involved at a post-receptor level. Analysis of the microarray data showed that 124 genes are differentially expressed through our classes of analysis (SAM analysis, FDR = 0%). These genes mainly play a role in specific immunity functions such as migration and cell–cell interactions, suggesting that, at least in vitro, leucocytes primed and unprimed show different responses to EPO-α treatment. We analysed these genes strictly in relation to cytokine signalling and observed that the signalling of IL-1 is significantly modulated by TNF-α/EPO-α synergy. Treatment...
Table 5. Effect of p38 and Erk1/2 selective inhibitors and EPO-α blockade on IL1B and IL8 gene expression in PBMCs. mRNA expression was determined by qPCR. The relative increase in mRNA expression (mean ± s.d., n = 10) is shown.

|            | IL1B (mean ± s.d.) | IL8 (mean ± s.d.) |
|------------|--------------------|-------------------|
| control    | 1.00 ± 0.09        | 1.00 ± 0.12       |
| TNF-α      | 2.63 ± 0.10        | 3.45 ± 0.20       |
| EPO-α      | 1.02 ± 0.08        | 0.97 ± 0.10       |
| anti-EPO-α | 1.08 ± 0.11        | 1.05 ± 0.12       |
| SB203580   | 0.96 ± 0.07        | 1.01 ± 0.09       |
| PD98059    | 1.09 ± 0.10        | 1.11 ± 0.14       |
| TNF-α + EPO-α | 6.11 ± 0.16**   | 1.05 ± 0.15*      |
| TNF-α + EPO-α + SB203580 | 8.28 ± 0.18** | 2.83 ± 0.21**    |
| TNF-α + EPO-α + PD98059   | 4.63 ± 0.21**     | 1.06 ± 0.11       |
| TNF-α + EPO-α + anti-EPO-α | 2.81 ± 0.25** | 3.25 ± 0.27**    |

*p < 0.05 versus PBMCs treated with TNF-α, **p < 0.05 versus PBMCs treated with TNF-α and EPO-α.

α-isofrom and the protein release is upregulated after treatment of cells with TNF-α and EPO-α. We did not observe any significant difference when treating PBMCs with either stimulus alone. We also found that EPO further increased CCL8 and induced de novo mRNA and protein expression of CXCL1 and CXCL5 in primed cells. IPA analysis suggested that these upregulations were significantly associated with upstream induction of IL-1α (Z-score > 2).

Drawing some first conclusions: we have confirmed that pro-inflammatory cytokines of the IL-1 family exert various EPO-α effects on PBMCs, whether primed or not. The cytokines IL-1α and β have already been strongly associated with establishment and maintenance of the anaemic state in CKD patients, inhibiting the in vitro growth of erythroid progenitors, exerting a negative interaction on iron homeostasis, damaging erythrocyte membranes, and therefore proving to be important molecules in eliciting a blunted response to EPO. Of note, the polymorphism IL1B-511-C/C, associated with a variety of diseases in which inflammation plays an important role, is at present considered as a genetic marker for the EPO requirement in haemodialysis patients [44]. Again, we propose the chemokines CXCL1, CXCL5 and CCL8 be considered as potential new biomarkers for EPO resistance. These chemokines are involved in the chemotraction of leucocytes to inflammatory sites and strongly contribute to chronic inflammation [45]. Moreover, the effect on erythroid precursor cell growth and iron metabolism has not yet been evaluated.

On the other hand, we show negative modulation in the case of important molecules involved both in the early stages and in the continuation of inflammation, confirming the anti-inflammatory effect of EPO previously described in vivo [16,17]. In particular, the expression and secretion of IL-8 was impaired by stimulation with TNF-α and abrogated by treatment with EPO-α. Similarly, gene coding for its receptor CXCR2 is significantly downregulated upon applying both stimuli. CXCR2 receptor can also bind other chemokines, including CXCL1 and CXCL5 [46]. Thus, downregulation of it plausibly involves a reduction of the potential pro-inflammatory effects exerted through CXCL1 and CXCL5 binding that are upregulated under the same experimental conditions. The inhibiting effect that EPO-α exerts on IL-8 expression in vitro could be significant in vivo. IL-8 is expressed mainly by monocytes and macrophages in the early stages of inflammation and persists for an extended period. This cytokine is responsible for the recruitment of neutrophils to the site of inflammation and subsequent activation of them [47]. What is more, through its angiogenic properties, IL-8 induces migration and proliferation of endothelial cells and smooth muscle cells, contributing to plaque formation in atherosclerosis [48]. It is reasonable to assume that this cytokine participates in the complexes that involve inflammation, malnutrition and atherosclerosis, and that portend a poor prognosis in CKD patients [49].

Nowadays, the only cytokine that is yet associated with ESA resistance is IL-6; it is in fact considered a strong predictor of ESA hyporesponsiveness in haemodialysis patients who have sufficient iron [50]. Among the cytokines and chemokines described in our work, none of them has been yet proposed as an ESA resistance predictor. Indeed, no study to date has investigated their levels in patients’ ESA-hyporesponsiveness versus control. However, some studies on rodents confirmed the trends reported in our results concerning the two most relevant pro-inflammatory cytokines involved in ESA resistance (i.e. IL-1β and IL-8). Wu et al. [51] showed that a dose of 300 U kg⁻¹ intravenous administration of EPO increases serum level of IL-1β. What is more, rats used in their experiments were sepsis-induced by LPS prior to EPO administration [51]. Furthermore, in another study it was proposed that a higher dose (1000 U kg⁻¹) of EPO intravenous administration reduced the serum level of IL-8 after induction of ischaemic/reperfusion process [52].

Altogether, our results showed that the effects of EPO-α on inflammatory mediator expression are elaborate and in some respects controversial. To further clarify the mechanisms that underlie these processes, we started by considering the post-receptor level, investigating the expression of MAPKs p38 and Erk1/2. In particular, p38 is reportedly involved in EPO receptor level, investigating the expression of MAPKs p38 and Erk1/2. These findings may be explained by previous studies, which observed that the very low amount of IL-8 found in quiescent cells is a result of very unstable mRNA, and that activation of the MAPK p38 pathway markedly stabilizes IL-8 mRNA [53]. Of note, more recently, Daulethäve et al. [55] suggested that the downregulation of TNF-induced IL-8 requires the inhibition of p38 via MAPK phosphatase 1-dependent and -independent mechanisms.

In addition, we show here that these forms of expression modulation were strongly blocked by Ab anti-EPO, indicating that EPO/EPOR binding is necessary in this process.

Our results also clearly demonstrate that the reduction in MAPK p38 activity induced by EPO-α in primed cells plays a part in strengthening IL-1β expression. The molecular mechanism by which this occurs might be explained by EPO-α
resulting in higher levels of MAPK Erk1/2 activity in primed cells. Interestingly, the pre-treatment of primed PBMCs treated with EPO-α by the selective inhibitor PD98059 significantly abrogates IL-1β secretion in conditioned medium. On the other hand, we did not report significant differences for IL-8 under the same experimental conditions.

Finally, we reported the downregulation exerted by EPO-α on genes encoding for FES in primed PBMCs. This kinase reducing the role of p38 in anti-inflammatory processes [34–36]. In this connection, we noted that potent and selective inhibition of MAPK p38 significantly increases IL-1β mRNA expression and secretion in primed cells treated with EPO-α. Blockage of EPO-α with selective antibody completely inhibits the process.

Furthermore, we showed that EPO-α induces higher levels of MAPK Erk1/2 activity in primed cells. Interestingly,
and FER protein (FES-related) are the only two members of a subfamily of proteins characterized by cytoplasmatic tyrosine kinase activity [56]. FES has been associated with growth factors and receptors for cytokines, which increase its catalytic activity by phosphorylation of tyrosine sites [57,58]. A role of FES in compartmentalization of myeloid and innate immunity has been highlighted through the study of mouse model knock-out or with a truncated form of this protein [56,59,60]. Of note, recent data on human erythroleukemia cells show that, following receptor stimulation upstream of FES, knock-out or with a truncated form of this protein [56,59,60].

In summary, our study reinforces the hypothesis that inflammation has a key role in EPO hyporesponsiveness/resistance. We were the first to describe the interesting modulation in gene expression of chemical mediators of inflammation. These genes are very likely to be involved in EPO resistance mechanisms and contribute to enriching the previously reported effects of EPO on immune cells. We have demonstrated that modulation of MAPK p38 and Erk1/2 activities seem to be involved in IL-1β expression regulation and activation of CASP-1 in secretion of this cytokine. Furthermore, reduction of p38 activity seems to be involved in EPO-α regulation of IL-8. The exact mechanisms of EPO-α treatment on primed cells remain to be clarified. To this end, we hope in future to further integrate our expression data with functional analysis of other kinases. We also intend to measure in vivo the molecular targets we have highlighted, in order to throw light on any additional markers in patients hyporesponsive to EPO.

Funding statement. The Italian Ministry for the University and Research is acknowledged for its financial support.

References

1. Voormolen N, Groenewold NA, Urengi IA, Boeschenstein ER, Sijpkens WY, Huisman RM, Krediet RT, Dekker FW. 2010 Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. Nephron. Clin. Pract. 115, c133 – c141. (doi:10.1159/000312876)

2. Escbach JW et al. 1989 Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992 – 1000. (doi:10.7326/0003-4819-111-12-992)

3. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, et al. 2009 Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 45, 154 – 157. (doi:10.1016/j.cyto.2008.12.005)

4. Keithy-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. 2008 Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 74, 782 – 790. (doi:10.1038/sj.ki.6.2008.245)

5. Tauxe I et al. 2005 The primed peripheral polymorphonuclear leukocyte—a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2431 – 2438. (doi:10.1681ASN.2004110929)

6. Barany P, Divino Filho JC, Bergstro¨m J. 2003 High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Int. J. Nephrol. Nephrol. 24, 39 – 47. (doi:10.1016/j.ijbne.2009.09.001)

7. Weiss G, Goodnough LT. 2005 Anemia of chronic disease. N. Engl. J. Med. 352, 1011 – 1023. (doi:10.1056/NEJMra041809)

8. Hojman P, Taudorf S, Lundby C, Pedersen BK. 2002 The polymorphonuclear leukocyte—a new target for erythropoietin. Nephron 88, 205 – 210. (doi:10.1159/000045991)

9. Goligorsky MS, Singh AK. 2008 Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 74, 782 – 790. (doi:10.1038/sj.ki.6.2008.245)

10. Allen DA, Breen C, Yangob MM, Macdougall IC. 2003 Expression of erythropoiesis inhibiting cytokines (IFN-γ and TNF-α) by T cells in patients exhibiting a poor response to erythropoietin therapy. J. Am. Soc. Nephrol. 14, 1776 – 1784. (doi:10.1097/01.ASN.0000071514.36428.61)

11. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. 2003 Increased expression of erythropoietin inhibiting cytokines (IFN-γ, TNF-α, IL-10, IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J. Am. Soc. Nephrol. 14, 1776 – 1784. (doi:10.1097/01.ASN.0000071514.36428.61)

12. Kaneko Y, Miyazaki S, Hirawaya Y, Gejyo F, Suzuki M. 2003 Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int. 63, 1086 – 1093. (doi:10.1046/j.1523-1755.2003.00262.x)

13. Lankhorst CE, Wish JB. 2010 Anemia in renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992 – 1000. (doi:10.7326/0003-4819-111-12-992)

14. Weiss G, Goodnough LT. 2005 Anemia of chronic disease. N. Engl. J. Med. 352, 1011 – 1023. (doi:10.1056/NEJMra041809)

15. Zhang YL, Radhakrishnan ML, Lu X, Gross AW, Tidor B, Lodish HF. 2009 Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex. Mol. Cell. 33, 266 – 274. (doi:10.1016/j.molcel.2008.11.026)

16. Kristal B, Shurtz-Swinski R, Tanhilevski O, Shapiro G, Shkolnik G, Chezar J, Suda T. 2002 Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 45, 154 – 157. (doi:10.1016/j.cyto.2008.12.005)

17. Keithy-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. 2008 Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 74, 782 – 790. (doi:10.1038/sj.ki.6.2008.245)

18. Tauxe I et al. 2005 The primed peripheral polymorphonuclear leukocyte—a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2431 – 2438. (doi:10.1681ASN.2004110929)

19. Kristal B, Shurtz-Swinski R, Tanhilevski O, Shapiro G, Shkolnik G, Chezar J, Sutksovsky T, Cohen-Mazor M, Suda T. 2008 Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming. Int. J. Nephrol. 10, 266 – 272.

20. Kirkby A, van Beek J, Nielsen J, Leist M, Helboe L. 2007 Functional and immunochemochemical characterisation of different antibodies against the erythropoietin receptor. J. Neurosci. Methods 164, 50 – 58. (doi:10.1016/j.jneumeth.2007.03.026)

21. Kotani K, Kawase K, Imamura R, Kinosita H, Kushiyama H, Suda T. 2010 Activation of ASC induces apoptosis or necrosis, depending on the cell type, and causes tumor reactivation. Cancer Sci. 101, 1822 – 1827. (doi:10.1111/j.1349-7006.2010.01650.x)

22. Kotani K, Kushiyama H, Imamura R, Kinosita T, Nishidori T, Suda T. 2011 Caspase-1 protein induces apoptosis-associated speck-like protein containing a
...caspase recruitment domain (ASC)-mediated necrosis independently of its catalytic activity. J. Biol. Chem. 286, 33 963 – 33 972. (doi:10.1074/jbc.M111.288223)

27. Pesce M et al. 2013 Positive correlation between serum interleukin-1β and state anger in rugby athletes. Aggress. Behav. 39, 141 – 148. (doi:10.1002/ab.21457)

28. Patruno A et al. 2012 Novel aminobenzyl-acetamide derivatives modulate the differential regulation of NO3s in LPS induced inflammatory response: role of PI3 K/Akt pathway. Biochim. Biophys. Acta 1820, 2095 – 2104. (doi:10.1016/j.bbagen.2012.08.014)

29. Patruno A, Pesce M, Mammone A, Speranza L, Grilli A, De Lusis MA, Felaco M, Reale M. 2012 Activity of matrix metalloproteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells. J. Cell Physiology 227, 2767 – 2774. (doi:10.1002/jcp.23024)

30. Manthey CL, Wang SW, Kinney SD, Yao Z. 1998 IL-1-dependent phosphorylation of the TAB3 regulatory factor mRNA stability and translation mainly by bacterial artificial chromosome-transgenic mice. J. Immunol. 181, 2522 – 2532. (doi:10.4049/jimmunol.181.4.2522)

31. Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, Okamoto T. 2000 The role of p38 mitogen-activated protein kinase, as a powerful regulator of LPS-induced mRNAs in monocytes. J. Leukoc. Biol. 64, 409 – 417.

32. Saatian B, Zhao Y, He D, Georas SN, Watkins T, Spannhake EW, Natarajan V. 2006 Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem. J. 393, 657 – 668. (doi:10.1042/BJ20050791)

33. Ma W, Lim W, Gee K, Acouin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A. 2001 The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc. Natl Acad. Sci. USA 94, 508 – 513. (doi:10.1073/pnas.94.2.508)

34. De Sepulveda P, Dubreuil P, De Sepulveda P. 2010 FES kinase participates in KIT-ligand induced chemotaxis. Int. Immunol. 22, 1522 – 1528. (doi:10.1093/intimm/dxl064)

35. Han S et al. 2013 Capillinarins inhibits iNOS, COX-2 expression, and proinflammatory cytokines in LPS-induced RAW 264.7 macrophages via the suppression of ERK, JNK, and NF-κB activation. Immunopharmacol. Immunotoxicol. 35, 34 – 42. (doi:10.1080/08990011.2012.673262)

36. Kogel KH, Lee TW, Ihm CG, Lee SH, Moon JY. 2008 Mechanism of self-processing in casein-8 compromises its apoptotic but not its nonapoptotic functions in myeloma-like nuclear factor kappa B deficient cells. J. Biol. Chem. 283, 25625 – 25636. (doi:10.1074/jbc.M107170200)

37. Manthey CL, Wang SW, Kinney SD, Yao Z. 1998 IL-1-dependent phosphorylation of the TAB3 regulatory factor mRNA stability and translation mainly by bacterial artificial chromosome-transgenic mice. J. Immunol. 181, 2522 – 2532. (doi:10.4049/jimmunol.181.4.2522)

38. Verder Putten K, Braam B, Jie KE, Gaullier CA. 2008 Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat. Clin. Pract. Nephrol. 4, 103 – 107. (doi:10.1038/nreneph0655)

39. Lopez-Castejon G, Brough D. 2011 Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 22, 189 – 195. (doi:10.1016/j.cytogfr.2011.10.001)

40. Van der Putten K, Braam B, Jie KE, Gaullier CA. 2008 Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat. Clin. Pract. Nephrol. 4, 47 – 57. (doi:10.1038/nreneph0655)

41. Patel S, Wachs TL, Shall H. 2011 Erythropoietin resistance: a potential cause of aplastic anemia and other anemias. Blood 117, 2869 – 2876. (doi:10.1182/blood-2010-03-273394)

42. Rovida E, Marra F, Baccarini M, Dello Sbarba P. 2000 IL-8 is an angiogenic factor in human coronary atherectomy specimens. Life Sci. 67, 1519 – 1526. (doi:10.1016/S0024-3205(00)00358-7)

43. Stevenson FT, Turck J, Locksley RM, Lovett DH. 1997 The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc. Natl Acad. Sci. USA 94, 508 – 513. (doi:10.1073/pnas.94.2.508)

44. Greer P. 2002 Closing in on the biological functions of Fps/Fes and Fer. Nat. Rev. Mol. Cell. Biol. 3, 278 – 289. (doi:10.1038/nrm788)

45. Sangrar W, Goswami D, Mawji N, Iskandar M, Di Marco S, Gallozu IE, Lands LC. 2011 Down-regulation of cytokine-interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms. J. Biol. Chem. 286, 15 998 – 16 007. (doi:10.1074/jbc.M110.205724)

46. Greer P. 2000 Constitutive activation of the MAPK pathway mediates fes-induced mitogenesis in murine macrophages. Blood 95, 3959 – 3963.

47. Sangran W, Gao Y, Bates B, Ziringbl R, Greer PA. 2004 Activated Fps/Fes tyrosine kinase regulates erythroid differentiation and survival. Exp. Hematol. 32, 935 – 945. (doi:10.1016/j.exphem.2004.07.004)

48. Ziringbl RA, Senis Y, Greer PA. 2002 Enhanced endotxin sensitivity in fps/fes-null mice with minimal defects in hematopoietic homeostasis. Mol. Cell. Biol. 22, 2472 – 2486. (doi:10.1128/MCB.22.8.2472-2486.2002)

49. Parsons SA, Greer PA. 2006 The Fps/Fes kinase regulates the inflammatory response to endotoxin through down-regulation of TLR4, NF-kappaB activation, and TNF-alpha secretion in macrophages. J. Leukoc. Biol. 80, 1522 – 1528. (doi:10.1189/jlb.0506350)

50. Voisiet E, Lopez S, Chaux A, Vita M, George C, Dubreuil P, De Sepulveda P. 2010 FES kinase participates in Kit-ligand induced chemotaxis. Biochem. Biophys. Res. Commun. 393, 174 – 178. (doi:10.1016/j.bbrc.2010.01.116)